United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - baricitinib - tablet - 4mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

eli lilly and company ltd - baricitinib - tablet - 2mg

European Union - English - EMA (European Medicines Agency)

eli lilly nederland b.v. - baricitinib - arthritis, rheumatoid - immunosuppressants - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant may be used as monotherapy or in combination with methotrexate.atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis.baricitinib may be used as monotherapy or in combination with methotrexate.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - baricitinib - film coated tablets - baricitinib 2 mg - baricitinib - rheumatoid arthritisolumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. olumiant may be used as monotherapy or in combination with methotrexate.atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.alopecia areataolumiant is indicated for the treatment of severe alopecia areata in adult patients.

Israel - English - Ministry of Health

eli lilly israel ltd, israel - baricitinib - film coated tablets - baricitinib 4 mg - baricitinib - rheumatoid arthritisolumiant is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs. olumiant may be used as monotherapy or in combination with methotrexate.atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult patients who are candidates for systemic therapy.alopecia areataolumiant is indicated for the treatment of severe alopecia areata in adult patients.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly nederland b.v., netherlands - baricitinib - film-coated tablet - 2 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly nederland b.v., netherlands - baricitinib - film-coated tablet - 2 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly nederland b.v., netherlands - baricitinib - film-coated tablet - 4 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

eli lilly nederland b.v., netherlands - baricitinib - film-coated tablet - 4 mg

Singapore - English - HSA (Health Sciences Authority)

dksh singapore pte. ltd. - baricitinib - tablet, film coated - baricitinib 2.000mg